Law360, New York (January 9, 2018, 7:04 PM EST) — The Patent Trial and Appeal Board on Monday invalidated several claims in an OSI Pharmaceuticals LLC patent that covers its cancer medication Tarceva, as part of an inter partes review requested by Apotex Inc. The board agreed with Apotex that …
